001     181934
005     20240229145701.0
024 7 _ |a 10.1016/j.ejca.2022.09.001
|2 doi
024 7 _ |a pmid:36182817
|2 pmid
024 7 _ |a 0014-2964
|2 ISSN
024 7 _ |a 0959-8049
|2 ISSN
024 7 _ |a 1879-0852
|2 ISSN
024 7 _ |a (1990)
|2 ISSN
024 7 _ |a 1879-2995
|2 ISSN
024 7 _ |a (1965)
|2 ISSN
024 7 _ |a altmetric:136581402
|2 altmetric
037 _ _ |a DKFZ-2022-02304
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Langenberg, Karin P S
|b 0
245 _ _ |a Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.
260 _ _ |a Amsterdam [u.a.]
|c 2022
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1664970163_8109
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a iTHER is a Dutch prospective national precision oncology program aiming to define tumour molecular profiles in children and adolescents with primary very high-risk, relapsed, or refractory paediatric tumours. Between April 2017 and April 2021, 302 samples from 253 patients were included. Comprehensive molecular profiling including low-coverage whole genome sequencing (lcWGS), whole exome sequencing (WES), RNA sequencing (RNA-seq), Affymetrix, and/or 850k methylation profiling was successfully performed for 226 samples with at least 20% tumour content. Germline pathogenic variants were identified in 16% of patients (35/219), of which 22 variants were judged causative for a cancer predisposition syndrome. At least one somatic alteration was detected in 204 (90.3%), and 185 (81.9%) were considered druggable, with clinical priority very high (6.1%), high (21.3%), moderate (26.0%), intermediate (36.1%), and borderline (10.5%) priority. iTHER led to revision or refinement of diagnosis in 8 patients (3.5%). Temporal heterogeneity was observed in paired samples of 15 patients, indicating the value of sequential analyses. Of 137 patients with follow-up beyond twelve months, 21 molecularly matched treatments were applied in 19 patients (13.9%), with clinical benefit in few. Most relevant barriers to not applying targeted therapies included poor performance status, as well as limited access to drugs within clinical trial. iTHER demonstrates the feasibility of comprehensive molecular profiling across all ages, tumour types and stages in paediatric cancers, informing of diagnostic, prognostic, and targetable alterations as well as reportable germline variants. Therefore, WES and RNA-seq is nowadays standard clinical care at the Princess Máxima Center for all children with cancer, including patients at primary diagnosis. Improved access to innovative treatments within biology-driven combination trials is required to ultimately improve survival.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Adolescent
|2 Other
650 _ 7 |a Cancer
|2 Other
650 _ 7 |a Child
|2 Other
650 _ 7 |a Hereditary
|2 Other
650 _ 7 |a Molecular biology
|2 Other
650 _ 7 |a Molecular targeted therapy
|2 Other
650 _ 7 |a Next-generation sequencing
|2 Other
650 _ 7 |a Precision medicine
|2 Other
700 1 _ |a Meister, Michael T
|b 1
700 1 _ |a Bakhuizen, Jette J
|b 2
700 1 _ |a Boer, Judith M
|b 3
700 1 _ |a van Eijkelenburg, Natasha K A
|b 4
700 1 _ |a Hulleman, Esther
|b 5
700 1 _ |a Ilan, Uri
|b 6
700 1 _ |a Looze, Eleonora J
|b 7
700 1 _ |a Dierselhuis, Miranda P
|b 8
700 1 _ |a van der Lugt, Jasper
|b 9
700 1 _ |a Breunis, Willemijn
|b 10
700 1 _ |a Schild, Linda G
|b 11
700 1 _ |a Ober, Kimberley
|b 12
700 1 _ |a van Hooff, Sander R
|b 13
700 1 _ |a Scheijde-Vermeulen, Marijn A
|b 14
700 1 _ |a Hiemcke-Jiwa, Laura S
|b 15
700 1 _ |a Flucke, Uta E
|b 16
700 1 _ |a Kranendonk, Mariette E G
|b 17
700 1 _ |a Wesseling, Pieter
|b 18
700 1 _ |a Sonneveld, Edwin
|b 19
700 1 _ |a Punt, Simone
|b 20
700 1 _ |a Boltjes, Arjan
|b 21
700 1 _ |a van Dijk, Freerk
|b 22
700 1 _ |a Verwiel, Eugene T P
|b 23
700 1 _ |a Volckmann, Richard
|b 24
700 1 _ |a Hehir-Kwa, Jayne Y
|b 25
700 1 _ |a Kester, Lennart A
|b 26
700 1 _ |a Koudijs, Marco M J
|b 27
700 1 _ |a Waanders, Esme
|b 28
700 1 _ |a Holstege, Frank C P
|b 29
700 1 _ |a Vormoor, H Josef
|b 30
700 1 _ |a Hoving, Eelco W
|b 31
700 1 _ |a van Noesel, Max M
|b 32
700 1 _ |a Pieters, Rob
|b 33
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 34
|u dkfz
700 1 _ |a Stumpf, Miriam
|b 35
700 1 _ |a Blattner-Johnson, Mirjam
|0 P:(DE-He78)261d2b84aded878003e6e35d18113831
|b 36
|u dkfz
700 1 _ |a Balasubramanian, Gnana P
|0 P:(DE-He78)e5bb26ffbde307745ae396c2e829dac5
|b 37
|u dkfz
700 1 _ |a Van Tilburg, Cornelis M
|0 P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271
|b 38
|u dkfz
700 1 _ |a Jones, Barbara C
|0 P:(DE-He78)fae1bf941c5fd76cf5356ecfa1243cc4
|b 39
|u dkfz
700 1 _ |a Jones, David T W
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 40
|u dkfz
700 1 _ |a Witt, Olaf
|0 P:(DE-He78)143af26de9d57bf624771616318aaf7c
|b 41
|u dkfz
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 42
|u dkfz
700 1 _ |a Jongmans, Marjolijn C J
|b 43
700 1 _ |a Kuiper, Roland P
|b 44
700 1 _ |a de Krijger, Ronald R
|b 45
700 1 _ |a Wijnen, Marc H W
|b 46
700 1 _ |a den Boer, Monique L
|b 47
700 1 _ |a Zwaan, C Michel
|b 48
700 1 _ |a Kemmeren, Patrick
|b 49
700 1 _ |a Koster, Jan
|b 50
700 1 _ |a Tops, Bastiaan B J
|b 51
700 1 _ |a Goemans, Bianca F
|b 52
700 1 _ |a Molenaar, Jan J
|b 53
773 _ _ |a 10.1016/j.ejca.2022.09.001
|g Vol. 175, p. 311 - 325
|0 PERI:(DE-600)1468190-0
|p 311 - 325
|t European journal of cancer
|v 175
|y 2022
|x 0014-2964
909 C O |o oai:inrepo02.dkfz.de:181934
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 34
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 36
|6 P:(DE-He78)261d2b84aded878003e6e35d18113831
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 37
|6 P:(DE-He78)e5bb26ffbde307745ae396c2e829dac5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 38
|6 P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 39
|6 P:(DE-He78)fae1bf941c5fd76cf5356ecfa1243cc4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 40
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 41
|6 P:(DE-He78)143af26de9d57bf624771616318aaf7c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 42
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-30
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J CANCER : 2021
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-30
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-30
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EUR J CANCER : 2021
|d 2022-11-30
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pediatric Glioma
|x 2
920 1 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a I:(DE-He78)B310-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21